|
May 12
|
Arcellx First Quarter 2024 Earnings: Beats Expectations
|
|
May 10
|
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
|
|
May 10
|
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
|
|
May 9
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Arcellx Provides First Quarter 2024 Financial Results
|
|
May 9
|
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
|
|
May 7
|
Arcellx to Participate in Two Upcoming Investor Conferences
|
|
Apr 23
|
Should You Be Bullish on Arcellx (ACLX)?
|
|
Apr 4
|
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Apr 4
|
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
|
|
Mar 29
|
Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors
|
|
Mar 28
|
Insiders Are Dumping These 10 Healthcare Stocks
|
|
Mar 27
|
Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
|
|
Mar 20
|
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
|
Jan 16
|
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
|
|
Dec 22
|
Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc
|
|
Dec 8
|
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
|
|
Nov 15
|
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
|